Last reviewed · How we verify
NCT05347316: COPIX
Colchicine Effect on Perivascular Inflammation Index on Coronary CTA
Phase 1 trial testing Colchicine in Atherosclerosis in 40 participants. Status unknown.
7 March 2023
Quick facts
| Lead sponsor | University of Sao Paulo General Hospital |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 7 March 2022 |
| Primary completion | 7 March 2023 |
| Estimated completion | 7 March 2025 |
| Sites | 1 location across Brazil |
Drugs / interventions tested
- Colchicine (COLCHICINE) — full drug profile →
Conditions studied
- Atherosclerosis — all drugs for Atherosclerosis →
- Inflammatory Response — all drugs for Inflammatory Response →
- Coronary Disease — all drugs for Coronary Disease →
Sponsor
University of Sao Paulo General Hospital
Who can join
18 and older, any sex, with Atherosclerosis or Inflammatory Response. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Inflammation is an important pillar of atherogenesis in coronary disease. Studies have documented the prognostic power of measuring coronary perivascular adipose tissue attenuation (PVAT) and its good correlation as an early inflammatory biomarker in the atherogenesis process, in addition to being a predictor for cardiovascular events in the future. Colchicine, a medication with well-documented anti-inflammatory action and with an impact on reducing cardiovascular outcomes, may have an action in reducing FAI (fat attenuation index). This study aims to evaluate the effect of colchicine in reducing coronary perivascular inflammation.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Endothelial mechanobiology in atherosclerosis.
Wang X, Shen Y, Shang M, Liu X, et al · · 2023 · cited 79× · PMID 37163659 · DOI 10.1093/cvr/cvad076 -
Perivascular fat attenuation index (FAI) on computed tomography coronary angiography reclassifies individual cardiovascular risk estimation.
Coerkamp CF, Verpalen VA, Kuipers RS, Driessen-Waaijer A, et al · · 2025 · cited 6× · PMID 39811144 · DOI 10.1016/j.ijcrp.2024.200360 -
Perspectives in the Diagnosis, Clinical Impact, and Management of the Vulnerable Plaque.
Alperi A, Antuna P, Almendárez M, Álvarez R, et al · · 2025 · PMID 40095464 · DOI 10.3390/jcm14051539
Verify or expand the search:
- PubMed search for NCT05347316
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Colchicine
Trials testing the same drug.
- NCT07476625 — Efficacy and Safety of Thalidomide for Pediatric PFAPA Syndrome · NA · not yet recruiting
- NCT06279000 — Colchicine in Patients at Cardiac Risk Undergoing Major Non-Cardiac Surgery · Phase 3 · recruiting
- NCT06813079 — Using Tumor Models to Determine Treatments · Phase 2 · not yet recruiting
- NCT06578182 — The Effect of ColcHicine on the Incidence of Knee or Hip Replacements · Phase 3 · recruiting
- NCT06203977 — Inflammation REduction to Prevent cArdiovascular Injury in Renal Disease (REPAIR) · Phase 1 · recruiting
Other recruiting trials for Atherosclerosis
Currently open trials in the same condition.
- NCT07448038 — A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vas · Phase 2 · recruiting
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT06788431 — A Clinical Study of IMC-001 for Injection in Improving Atherosclerotic Plaque Stability in Patients With Acute Coronary · EARLY_PHASE1 · recruiting
- NCT06676046 — Natural History of Uncommon Dyslipidemias, Rare Lipid Disorders and Unusual Atherosclerotic Conditions · recruiting
- NCT06694012 — Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2 · recruiting
Other University of Sao Paulo General Hospital trials
Trials by the same sponsor.
- NCT07275580 — Antibiotic Prophylaxis After Simple Tooth Extraction in Immunosuppressed Patients With Autoimmune Rheumatic Diseases · Phase 4 · not yet recruiting
- NCT07478094 — Longitudinal Outcomes of Patients With Group 3 Pulmonary Hypertension Treated With Iloprost · not yet recruiting
- NCT07341386 — Prevention of Recurrence of Herpes Simplex in Autoimmune Rheumatic Diseases · Phase 4 · not yet recruiting
- NCT07242092 — Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs · Phase 4 · not yet recruiting
- NCT07484152 — Motor and Non-Motor Effects of Low-Intensity Focused Ultrasound (LIFU) as a Neuromodulation Tool in Essential Tremor · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05347316 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Sao Paulo General Hospital
- Last refreshed: 9 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05347316.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing